Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT02234284 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Aides in Respiration Health Coaching for COPD

AIR
Start date: November 12, 2014
Phase: N/A
Study type: Interventional

This study examined whether health coaches can improve the management of chronic obstructive pulmonary disease (COPD) in a population of vulnerable patients cared for in 'safety-net' clinics. The study is designed as a randomized controlled trial for patients with moderate to severe COPD. Patients were randomized into a health coaching group and a usual care group. Those in the health coaching group received 9 months of active health coaching. Outcome variables were measured at baseline and after 9 months

NCT ID: NCT02234128 Completed - Lung Disease Clinical Trials

Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility

Start date: July 18, 2015
Phase: N/A
Study type: Interventional

This is a safety study to compare the safety of receiving a lung treated with the Toronto EVLP System™ by SPONSOR in SPONSOR's dedicated facility against standard lung transplantation.

NCT ID: NCT02233907 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease

Start date: October 1999
Phase: N/A
Study type: Observational

Study to obtain further information on the tolerability and efficacy of Ventilat® metered dose inhaler in long-term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02233894 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Start date: February 2001
Phase: N/A
Study type: Observational

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02233881 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Start date: January 2001
Phase: N/A
Study type: Observational

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02233686 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

Start date: February 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD). The effectiveness of XEN-D0501 placebo in reducing capsaicin cough responses, objective 24-hour cough frequency, hourly change in cough frequency, cough severity (via visual analogue scale [VAS]), urge to cough (via VAS), global rating of change scale, Clinical COPD Questionnaire (CCQ), Leicester Cough Questionnaire (LCQ), and St George's Respiratory Questionnaire (SGRQ-C) will be evaluated.

NCT ID: NCT02233543 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 30, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study was to determine whether a fixed dose combination of indacaterol and glycopyrronium (QVA149) has an impact on night-time blood oxygen levels in Chronic Obstructive Pulmonary Disease.

NCT ID: NCT02231346 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease

Start date: October 2005
Phase: N/A
Study type: Observational

New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® compared to a powder inhaler in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®

NCT ID: NCT02231320 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease

Start date: December 2005
Phase: N/A
Study type: Observational

New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®

NCT ID: NCT02231177 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the systemic exposure to BI 1744 BS and tiotropium at steady state following inhalation of the fixed dose combination (FDC) of 10 μg BI 1744 CL plus 5 μg tiotropium bromide with the systemic exposure to BI 1744 BS and tiotropium at steady state following inhalation of the single agents, i.e., 10 μg BI 1744 CL and 5 μg tiotropium bromide, when administered once-daily via the Respimat® Inhaler for 21 days. The secondary objectives were to compare the safety and tolerability (adverse events, 12-lead electrocardiogram recordings, pulmonary function testing) of BI 1744 CL and tiotropium bromide when administered as fixed dose combination or as single-agent therapy.